WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, reported its financial results for the third quarter ended September 30, 2016, and provided a business update. As of September 30, 2016, Radius had $369.8 million in cash, cash equivalents and marketable securities.
“We are working closely with the U.S. Food and Drug Administration and the European Medicines Agency as they review our regulatory submissions for abaloparatide-SC, and building our commercial capabilities for a successful launch, pending favorable review,” said Robert Ward, President and Chief Executive Officer of Radius. “We are positioning our company for sustainable growth, and pleased to have made substantial progress in the development of a transdermal patch line extension for abaloparatide and in advancing our two oncology programs.”
